Therapeutic Strategies to Address Monkeypox

Overview

Journal Expert Rev Anti Infect Ther

Specialty Infectious Diseases

Date 2022 Aug 11

PMID 35953443

Authors

Matthew W McCarthy

Affiliations

Soon will be listed here.

Abstract

Introduction: Monkeypox is a viral zoonosis, with symptoms similar to those seen in smallpox patients, although the clinical presentation may be less severe. Until recently, human monkeypox infection was rare, and primarily occurred in Central and West Africa.

Areas Covered: An international outbreak began in May 2022, and monkeypox has now been detected on every continent except Antarctica. The first recognized case from the current outbreak was confirmed in the United Kingdom on 6 May 2022, in an adult with travel links to Nigeria, but it has been suggested that cases had been spreading in Europe for months. On 23 July 2022 the Director-General of the World Health Organization declared the monkeypox outbreak a public health emergency of international concern.

Expert Opinion: There are no treatments specifically for monkeypox virus infections. However, monkeypox and smallpox viruses are genetically similar, and therapeutics developed to combat smallpox may be used to treat monkeypox. This manuscripts reviews what is known about these potential treatments, including tecovirimat and brincidofovir, based on a literature search of PubMed through 9 August 2022, and explores how these therapeutics may be used in the future to address the expanding monkeypox pandemic.

Citing Articles

The Feasibility of Elimination of Monkeypox Virus in Nigeria: A Systematic Review.

Lawrence A, Anejo-Okopi J, Adeseye B Cureus. 2024; 16(6):e61867.

PMID: 38978921 PMC: 11228412. DOI: 10.7759/cureus.61867.

Monkeypox: Immune response, vaccination and preventive efforts.

Ophinni Y, Frediansyah A, Sirinam S, Megawati D, Stoian A, Enitan S Narra J. 2024; 2(3):e90.

PMID: 38449905 PMC: 10914130. DOI: 10.52225/narra.v2i3.90.

The re-emergence and transmission of Monkeypox virus in Nigeria: the role of one health.

Ogunleye S, Akinsulie O, Aborode A, Olorunshola M, Gbore D, Oladoye M Front Public Health. 2024; 11:1334238.

PMID: 38249416 PMC: 10797020. DOI: 10.3389/fpubh.2023.1334238.

When it rains, it pours: Early treatment with tecovirimat of cardiac complications associated with monkeypox infection in a person with HIV and previously undiagnosed Lyme disease. A case report.

Lagi F, Formica G, Rostagno A, Milia A, Pradella S, Guazzini G Heliyon. 2024; 10(1):e23965.

PMID: 38226256 PMC: 10788526. DOI: 10.1016/j.heliyon.2023.e23965.

Mapping the Landscape of Health Research Priorities for Effective Pandemic Preparedness in Human Mpox Virus Disease.

Aggarwal S, Agarwal P, Nigam K, Vijay N, Yadav P, Gupta N Pathogens. 2023; 12(11).

PMID: 38003816 PMC: 10674790. DOI: 10.3390/pathogens12111352.

References

Voigt S, Hofmann J, Edelmann A, Sauerbrei A, Kuhl J . Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. Transpl Infect Dis. 2016; 18(5):791-794. DOI: 10.1111/tid.12582. View

Thabane L, Lancaster G . Improving the efficiency of trials using innovative pilot designs: the next phase in the conduct and reporting of pilot and feasibility studies. Pilot Feasibility Stud. 2017; 4:14. PMC: 5501345. DOI: 10.1186/s40814-017-0159-2. View

Quarleri J, Delpino M, Galvan V . Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. Geroscience. 2022; 44(4):2095-2103. PMC: 9208705. DOI: 10.1007/s11357-022-00611-6. View

Taseen S, Nasir F, Abbas M, Altaf M, Asghar M, Junaid Tahir M . Post-pandemic world at the mercy of monkeypox virus outbreak: Time to worry or not?. J Med Virol. 2022; 95(1):e27948. DOI: 10.1002/jmv.27948. View

Laudisoit A, Tepage F, Colebunders R . Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med. 2018; 379(21):2084-2085. DOI: 10.1056/NEJMc1811044. View

Chavda V, Apostolopoulos V . Rare monkeypox: Is it really a threat to the elderly?. Maturitas. 2022; 163:90-91. PMC: 9192136. DOI: 10.1016/j.maturitas.2022.05.014. View

Adler H, Gould S, Hine P, Snell L, Wong W, Houlihan C . Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022; 22(8):1153-1162. PMC: 9300470. DOI: 10.1016/S1473-3099(22)00228-6. View

Dodd L, Freidlin B, Korn E . Platform Trials - Beware the Noncomparable Control Group. N Engl J Med. 2021; 384(16):1572-1573. PMC: 8117966. DOI: 10.1056/NEJMc2102446. View

Hill B . The 2022 multinational monkeypox outbreak in non-endemic countries. Br J Nurs. 2022; 31(12):664-665. DOI: 10.12968/bjon.2022.31.12.664. View

10.

Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L . Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022; 27(22). PMC: 9164677. DOI: 10.2807/1560-7917.ES.2022.27.22.2200422. View

11.

Saxena S, Ansari S, Maurya V, Kumar S, Jain A, Paweska J . Re-emerging human monkeypox: A major public-health debacle. J Med Virol. 2022; 95(1):e27902. DOI: 10.1002/jmv.27902. View

12.

Quenelle D, Prichard M, Keith K, Hruby D, Jordan R, Painter G . Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother. 2007; 51(11):4118-24. PMC: 2151443. DOI: 10.1128/AAC.00762-07. View

13.

Challenger A, Sumner P, Bott L . COVID-19 myth-busting: an experimental study. BMC Public Health. 2022; 22(1):131. PMC: 8767039. DOI: 10.1186/s12889-021-12464-3. View

14.

Grosenbach D, Honeychurch K, Rose E, Chinsangaram J, Frimm A, Maiti B . Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med. 2018; 379(1):44-53. PMC: 6086581. DOI: 10.1056/NEJMoa1705688. View

15.

Bolken T, Hruby D . Tecovirimat for smallpox infections. Drugs Today (Barc). 2010; 46(2):109-17. DOI: 10.1358/dot.2010.46.2.1437244. View

16.

Chinsangaram J, Honeychurch K, Tyavanagimatt S, Leeds J, Bolken T, Jones K . Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother. 2012; 56(9):4900-5. PMC: 3421894. DOI: 10.1128/AAC.00904-12. View

17.

Collignon O, Burman C, Posch M, Schiel A . Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome. Clin Pharmacol Ther. 2021; 110(2):311-320. PMC: 8014457. DOI: 10.1002/cpt.2183. View

18.

De Clercq E . Historical perspectives in the development of antiviral agents against poxviruses. Viruses. 2011; 2(6):1322-1339. PMC: 3185982. DOI: 10.3390/v2061322. View

19.

Anderson M, Frenkel L, Homann S, Guffey J . A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. Pediatr Infect Dis J. 2003; 22(12):1093-6. DOI: 10.1097/01.inf.0000101821.61387.a5. View

20.

Weiner Z, Salzer J, LeMasters E, Ellison J, Kondas A, Morgan C . Characterization of Monkeypox virus dissemination in the black-tailed prairie dog (Cynomys ludovicianus) through in vivo bioluminescent imaging. PLoS One. 2019; 14(9):e0222612. PMC: 6762066. DOI: 10.1371/journal.pone.0222612. View